lynda

Psoriatic Arthritis - Global Drug Forecast And Market Analysis To 2025

Press Release   •   Aug 16, 2017 07:33 EDT

Psoriatic Arthritis - Global Drug Forecast And Market Analysis To 2025

Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially those of the lower extremities and distal joints of the fingers and toes as well as the back and sacroiliac joints of the pelvis. In approximately 80% of PsA patients, skin lesions of psoriasis (PsO), an immune-mediated skin disease, manifest prior to the development of PsA, typically by five to 10 years. PsA most commonly develops between the ages of 30 and 50 and affects men and women equally. Although, early diagnosis and intervention are key in preventing irreversible joint damage, many PsA patients are undiagnosed and go untreated for months or years.

Download sample pages of this report:https://goo.gl/cPyYcS

Global Data projects the PsA market in 7MM to experience strong growth during the forecast period at a CAGR of 10.74%. By the forecast€™s end in 2025, sales will increase to over $12.58 billion from $4.53 billion in 2015. This growth will be driven primarily by the increase in diagnosed prevalent cases from 1,044,022 in 2015 to 1,520,471 in 2025. Further, the launch of the IL-17 inhibitors, including Novartis’ Cosentyx, Eli Lilly’s Taltz, and AstraZeneca’s Lumicef, as well as the launch of Celgene’s oral therapy Otezla, will expand the treatment armamentarium for PsA driving growth in the market.

Scope

Overview of PsA, including epidemiology, etiology, pathophysiology, symptoms and country-specific diagnosis and treatment recommendations.

Annualized PsA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the PsA market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of novel products- including promising IL-17 inhibitors – and biosimilars – such as Celltrion’s Hospira, Sandoz’s Erelzi, Biogen/Samsung Bioepies’ Flixabi and Benepali, and Amgen’s Amjevita.

Analysis of the current and future market competition in the global PsA market (7MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Download sample pages of this report:https://goo.gl/cPyYcS

About Us:

Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

sales@kminsights.com

+1 (888) 278-7681